secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-05-28T13:01:18+00:00
Accession:  0001628280-26-038630
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors
--------------------------------------------------------------------------------

- Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.
- Robert More appointed Audit Committee Chair; board size reduced from 8 to 7 upon Ramasastry's departure.
- At May 26 annual meeting, Class I directors Robert More, Janet Napolitano, and Elliott Sigal elected; Napolitano received 67.2M for, 54.5M withheld.
- Advisory vote on named executive officer compensation approved: 108.5M for, 11.9M against, 1.4M abstain.
- Ratification of Ernst & Young as independent auditor for FY2026 approved: 137.0M for, 0.15M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/vir-20260525.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-038630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer